TY - JOUR
T1 - Development of individual fitness score for conformity of prescriptions to the “Guidelines For Pharmacological Therapy of Schizophrenia”
AU - Inada, Ken
AU - Fukumoto, Kentaro
AU - Hasegawa, Naomi
AU - Yasuda, Yuka
AU - Yamada, Hisashi
AU - Hori, Hikaru
AU - Ichihashi, Kayo
AU - Iida, Hitoshi
AU - Ohi, Kazutaka
AU - Muraoka, Hiroyuki
AU - Kodaka, Fumitoshi
AU - Ide, Kenta
AU - Hashimoto, Naoki
AU - Iga, Jun ichi
AU - Ogasawara, Kazuyoshi
AU - Atake, Kiyokazu
AU - Takaesu, Yoshikazu
AU - Nagasawa, Tatsuya
AU - Komatsu, Hiroshi
AU - Okada, Tsuyoshi
AU - Furihata, Ryuji
AU - Kido, Mikio
AU - Kikuchi, Saya
AU - Kubota, Chika
AU - Makinodan, Manabu
AU - Ochi, Shinichiro
AU - Takeshima, Masahiro
AU - Yamagata, Hirotaka
AU - Matsumoto, Junya
AU - Miura, Kenichiro
AU - Usami, Masahide
AU - Kishimoto, Taishiro
AU - Onitsuka, Toshiaki
AU - Katsumoto, Eiichi
AU - Hishimoto, Akitoyo
AU - Numata, Shusuke
AU - Yasui-Furukori, Norio
AU - Watanabe, Koichiro
AU - Hashimoto, Ryota
N1 - Funding Information:
This project was funded by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP16dk0307060, JP19dk0307083, and JP22dk0307112, JSPS KAKENHI Grant Number JP21K17261, the Health and Labor Sciences Research Grants (H29‐Seishin‐Ippan‐001, 19GC1201), the Japanese Society of Neuropsychopharmacology, the Japanese Society of Mood Disorders, the Japanese Society of Clinical Neuropsychopharmacology, and the Japanese Society of Psychiatry and Neurology. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2022 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
PY - 2022/12
Y1 - 2022/12
N2 - Aims: The Guidelines for the Pharmacotherapy of Schizophrenia were established to improve the quality of medical care, and the EGUIDE project was conducted to train clinicians on guideline usage. A quality indicator (QI) was established to measure the prevalence of the guidelines, and a survey was conducted, which revealed a gap between the guidelines and actual clinical practice (evidence-practice-gap). The purpose of this study was to develop an individual fitness score (IFS) formula that expresses the degree to which prescribers adhere to the Guidelines for Pharmacological Therapy of Schizophrenia in a simple manner, and to determine the validity of this formula from a survey of the prescriptions of the EGUIDE project participants'. Methods: To establish appropriate scores, members discussed the proposed formula and then voted on them. The IFS formula developed was set up so that antipsychotic monotherapy would be given 100 points, with points deducted if concomitant or adjunctive antipsychotic medications were used, and a minimum score of 0. To validate this formula, prescriptions of hospitalized schizophrenic patients at admission and at discharge were scored and compared. Result: IFS points vary and ranged from 0 to100. The average pre-admission score for all subjects was 45.6, and the average score at discharge was 54, those were significantly higher during discharge. Conclusions: We developed an IFS formula, a tool to easily visualize the degree to which current prescriptions conform to the guidelines for the pharmacological treatment of schizophrenia.
AB - Aims: The Guidelines for the Pharmacotherapy of Schizophrenia were established to improve the quality of medical care, and the EGUIDE project was conducted to train clinicians on guideline usage. A quality indicator (QI) was established to measure the prevalence of the guidelines, and a survey was conducted, which revealed a gap between the guidelines and actual clinical practice (evidence-practice-gap). The purpose of this study was to develop an individual fitness score (IFS) formula that expresses the degree to which prescribers adhere to the Guidelines for Pharmacological Therapy of Schizophrenia in a simple manner, and to determine the validity of this formula from a survey of the prescriptions of the EGUIDE project participants'. Methods: To establish appropriate scores, members discussed the proposed formula and then voted on them. The IFS formula developed was set up so that antipsychotic monotherapy would be given 100 points, with points deducted if concomitant or adjunctive antipsychotic medications were used, and a minimum score of 0. To validate this formula, prescriptions of hospitalized schizophrenic patients at admission and at discharge were scored and compared. Result: IFS points vary and ranged from 0 to100. The average pre-admission score for all subjects was 45.6, and the average score at discharge was 54, those were significantly higher during discharge. Conclusions: We developed an IFS formula, a tool to easily visualize the degree to which current prescriptions conform to the guidelines for the pharmacological treatment of schizophrenia.
UR - http://www.scopus.com/inward/record.url?scp=85139910344&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139910344&partnerID=8YFLogxK
U2 - 10.1002/npr2.12293
DO - 10.1002/npr2.12293
M3 - Article
C2 - 36254805
AN - SCOPUS:85139910344
SN - 2574-173X
VL - 42
SP - 502
EP - 509
JO - Neuropsychopharmacology Reports
JF - Neuropsychopharmacology Reports
IS - 4
ER -
